Our Pipeline

Pioneering the development of therapeutics to modulate DNA Damage Response

DNA Damage Response Modulators

Our pipeline of DNA Damage Response modulators includes novel inhibitors of ATR and WEE1.

 

ATRN-119: Novel macrocyclic ATR inhibitor

  • Unique biomarkers identified for optimized patient selection

  • Differentiated, macrocyclic molecular structure

  • Potential for lower hematological toxicity versus other ATR inhibitors

  • Phase 1 clinical trial commenced 1Q, 2023

 

ATRN-W1051: Novel WEE1 inhibitor

  • Promising anti-tumor activity in tumor model

  • Potential for improved PK properties versus other WEE1 inhibitors

  • Excellent selectivity for WEE1 versus PLK1/2/3, potentially limiting off-target toxicity

  • Nanomolar anti-proliferative activity against multiple cancer cell lines

  • IND filing anticipated 4Q, 2023

DDR PIPELINE

MOLECULE
TARGET
INDICATION
BIOMARKER
Preclinical
IND-Enabling
Phase 1
Anticipated Milestones
ATRN-119
ATRN-1051
ATRN-354 1
APRE-DDRi
ATR
WEE1
ATR
DDR Target
Advanced solid tumors
Ovarian cancer, others
Advanced solid tumors
Advanced solid tumors
RepliBiom2
Profiling
CCNE
Amplification,
Others
Undisclosed
Undisclosed
Q1 2024 Phase 1 Results
End of 2023 IND Submission
Q4 2024 IND Submission
Q2 2024 Lead Candidate
1ATRN-354 timeline and anticipated milestones subject to data from ATRN-119 clinical trial
2RepliBiom - a synthetic lethality discovery platform

DDR PIPELINE